IP Library Granted Patent US 11,890,412
Granted Patent B2
US 11,890,412 · App. 17/164,371 · Granted Feb 6, 2024

Nozzles for nasal drug delivery

Inventors: John D. Hoekman (Seattle, WA); Michael Hite (Normandy Park, WA); Alan Brunelle (Woodinville, WA); Joel Relethford (Everett, WA)
Assignee: Impel Pharmaceuticals Inc.
A61M15/08A61M15/0021A61M16/127B05B1/14B05B7/08A61M16/208A61M2202/064A61M2210/0612A61M2210/0618A61M2210/1067A61M2210/1475
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,890,412
App. No.
17/164,371
Granted
Feb 6, 2024
Kind
B2
Abstract

A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.

Claims (26)

1. A method for delivering a compound to an upper olfactory region of a nasal cavity, the method comprising:

responsive to a nozzle being actuated, the nozzle positioned for intranasal delivery of the compound to a subject, wherein actuating the nozzle pressurizes a proximal end of the nozzle, the nozzle including a drug product inlet at the proximal end of the nozzle and a nozzle body defining a plurality of channels along a longitudinal axis, wherein the channels are disposed parallel to the longitudinal axis and are symmetric about a circle around the longitudinal axis:

transporting a propellant from a propellant chamber and the compound from a compound chamber through the drug product inlet, the drug product inlet configured to receive a mixture of the propellant and the compound;

transporting the mixture from the drug product inlet and through each of the plurality of channels, each of the plurality of channels having a proximal end and a distal end, the proximal end of each of the plurality of channels configured to receive the mixture, the distal end of each of the plurality of channels having an outlet orifice exiting to the nasal cavity; and

releasing the mixture from the outlet orifices of each of the plurality of channels directly into the nasal cavity, wherein once exited, the mixture forms a plume having a width of 5 degrees or less to enable the plume to reach the upper olfactory region of a nasal cavity.

2. The method of claim 1 , wherein each of the plurality of channels is a circular, tube-shaped channel.

3. The method of claim 1 , wherein the plume has a deposition width of 2.18 millimeters or less at a distance of 4 centimeters relative to the outlet orifices.

4. The method of claim 1 , wherein the plume has a deposition width of 1.95 millimeters or less at a distance of 4 centimeters relative to the outlet orifices.

5. The method of claim 1 , wherein the plume has a deposition width of 1.36 millimeters or less at a distance of 4 centimeters relative to the outlet orifices.

6. The method of claim 1 , wherein the plume has a deposition width between 1.36 millimeters and 2.87 millimeters at a distance of 4 centimeters relative to the outlet orifices.

7. The method of claim 1 , wherein the compound is a liquid, a powder, a gas, or combinations thereof.

8. The method of claim 1 , wherein the nozzle comprises between four to eleven channels.

9. The method of claim 1 , wherein the nozzle and the compound chamber are of uniform construction.

10. The method of claim 1 , wherein the propellant is a liquid, a gas, or combinations thereof.

11. The method of claim 1 , wherein drug product inlet is contiguous with the proximal end of the nozzle.

12. A method for delivering a compound to an upper olfactory region of a nasal cavity, the method comprising:

responsive to a nozzle being actuated, the nozzle positioned for intranasal delivery of the compound to a subject, wherein actuating the nozzle pressurizes a proximal end of the nozzle, the nozzle including a nozzle body defining a plurality of channels and a longitudinal axis, wherein the channels are disposed parallel to the longitudinal axis and are symmetric about a circle around the longitudinal axis:

transporting a mixture of a propellant and the compound through a drug product inlet of the nozzle, the drug product inlet disposed at the proximal end of the nozzle;

transporting the mixture from the drug product inlet and through each of the plurality of channels, each of the plurality of channels having a proximal end and a distal end, the proximal end of each of the plurality of channels configured to receive the mixture, the distal end of each of the plurality of channels having an outlet orifice exiting to the nasal cavity; and

releasing the mixture from the outlet orifices of each of the plurality of channels directly into the nasal cavity, wherein the mixture exits the nozzle in a direction parallel to the longitudinal axis and forms a plume having a plume angle that does not exceed 5 degrees to enable the plume to reach the upper olfactory region of a nasal cavity.

13. The method of claim 12 , wherein each of the plurality of channels is a circular, tube-shaped channel.

14. The method of claim 12 , wherein the propellant is a liquid, a gas, or combinations thereof.

15. The method of claim 12 , wherein the plume has a deposition width between 1.36 millimeters and 2.87 millimeters at a distance of 4 centimeters relative to the outlet orifices.

16. The method of claim 12 , wherein the compound is a liquid, a powder, a gas, or combinations thereof.

17. The method of claim 12 , wherein the nozzle comprises between four to eleven channels.

18. The method of claim 12 , wherein drug product inlet is contiguous with the proximal end of the nozzle.

Assignments (10)
SECURITY INTEREST Recorded Jun 5, 2025
From: WOODWARD SPECIALTY LLC
To: ALTER DOMUS (US) LLC
Reel/Frame 071324/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2024
From: JN BIDCO LLC
To: WOODWARD SPECIALTY LLC
Reel/Frame 067062/0344 →
SECURITY INTEREST Recorded Mar 20, 2024
From: JN BIDCO LLC
To: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
Reel/Frame 066837/0144 →
RELEASE OF SECURITY INTEREST Recorded Feb 28, 2024
From: OAKTREE FUND ADMINISTRATION, LLC
To: IMPEL PHARMACEUTICALS, INC.
Reel/Frame 066699/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2024
From: IMPEL PHARMACEUTICALS INC.
To: JN BIDCO LLC
Reel/Frame 066601/0479 →
CORRECTIVE ASSIGNMENT TO CORRECT THE REMOVAL OF APPLICATION NUMBERS 12866448 AND APLICATION NUMBER 14292481 PREVIOUSLY RECORDED AT REEL: 059790 FRAME: 0722. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 4, 2022
From: IMPEL NEUROPHARMA, INC.
To: IMPEL PHARMACEUTICALS INC.
Reel/Frame 059855/0252 →
CHANGE OF NAME Recorded Apr 25, 2022
From: IMPEL NEUROPHARMA, INC.
To: IMPEL PHARMACEUTICALS INC.
Reel/Frame 059790/0722 →
SECURITY INTEREST Recorded Mar 17, 2022
From: IMPEL NEUROPHARMA, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 059300/0433 →
SECURITY INTEREST Recorded Mar 17, 2022
From: IMPEL NEUROPHARMA, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 059300/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: HOEKMAN, JOHN D.; HITE, MICHAEL; BRUNELLE, ALAN; RELETHFORD, JOEL
To: IMPEL NEUROPHARMA, INC.
Reel/Frame 055148/0790 →
Continuity (5)
Continuation 15890266 · Feb 6, 2018
Continuation 14075126 · Nov 8, 2013
Continuation PCTUS2012037132 · May 9, 2012
Provisional Application 61484048 · May 9, 2011
Related Publication 20210322689A1 · Oct 21, 2021